Responsive nanomedicine strategies achieve pancreatic cancer precise theranostics

Pancreatic ductal adenocarcinoma (PDAC), the predominant subtype of pancreatic cancer, ranks among the deadliest malignancies worldwide, with a 5-year survival rate remaining below 13 %. Its poor prognosis stems from complex anatomical barriers, a dense and heterogeneous tumor microenvironment (TME), and intricate molecular regulatory networks that collectively hinder early detection and limit therapeutic efficacy. Nanomedicine offers promising solutions by enhancing drug loading, improving delivery, counteracting drug resistance, and enabling stimuli-responsive control. Notably, stimuli-responsive nanotherapeutics have emerged as a transformative strategy, achieving precise drug release through activation by endogenous TME cues (e.g., acidic pH, redox gradients, hypoxia, enzyme overexpression) or exogenous triggers (e.g., ultrasound, light, magnetic fields). Endogenous-responsive systems autonomously activate at tumor sites, enhancing intratumoral drug accumulation and reducing off-target effects, while exogenous-responsive platforms enable spatiotemporal control through external modulation. Multi-responsive systems integrate both mechanisms to achieve dynamic and synergistic therapeutic effects, holding significant promise for PDAC theranostics. This review summarizes recent advances in stimuli-responsive nanotherapeutics for PDAC, detailing their activation mechanisms, biomedical applications, and theranostic potential across endogenous, exogenous, and multi-responsive modalities. It further discusses current challenges and future directions for translating these technologies into clinical practice.Image 1Responsive nanotherapeutic strategies, by virtue of their precise responsiveness to various response sources, demonstrate unique advantages in pancreatic cancer treatment and have attracted extensive attention. This review systematically expounds the core mechanisms by which the strategy achieves stepwise overcoming of the complex anatomical barriers, tumor microenvironment, and molecular network in pancreatic cancer, as well as the synergistic enhancement of traditional and emerging strategies in pancreatic cancer treatment through independent or multiple responses. Finally, it explores the future directions for realizing personalized treatment of pancreatic cancer based on innovative responsive nanotechnology.View The PDF